Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
recMAGE-A3 + AS15 in unresectable MAGE-A3-positive metastatic cutaneous melanoma
2008-004007-64Phase 2Terminated
- Sponsor
- GSK
- Start
- Mar 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recMAGE-A3 + AS15 in cutaneous melanoma (CM), sponsored by GSK. Primary endpoint: 1-year overall survival rate. Started Mar 2009; status: terminated.
02
Drugs
recMAGE-A3 + AS15
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2008-004007-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004007-64.